SS-31 Peptide (Elamipretide): Dosage, Protocol, Reconstitution, and Mitochondrial Health Guide
SS-31 (Elamipretide)
SS-31, also known as elamipretide, is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane and has been studied for effects on mitochondrial bioenergetics and oxidative stress. Elamipretide is now FDA-approved as Forzinity for improving muscle strength in certain patients with Barth syndrome, while use outside that indication remains indication-specific or investigational.
How SS-31 Works
Cardiolipin Binding → Mitochondrial Membrane Stabilization → Bioenergetics Research
SS-31 selectively associates with cardiolipin in the inner mitochondrial membrane. Research has investigated how this interaction affects respiratory-chain organization, mitochondrial energetics, and oxidative-stress signaling. Clinical effects vary substantially by disease and study population.
Typical Research Protocol
10 mg vial + 1.0 mL BAC Water → 1 unit = 0.1 mg → Practical Real-World Mitochondrial Support
Standard Setup
Vial10 mg
Water1.0 mL bacteriostatic water
Concentration10 mg/mL
Conversion1 unit = 0.1 mg
Weeks 1–2
Starting Phase
Dose5 mg daily
Units50 units
Volume0.50 mL
Weeks 3–8
Standard Research-Use Range
Dose10–20 mg daily
Units100–200 units
Volume1.0–2.0 mL
Volume Note:
At the 10 mg/mL concentration shown here, 10 mg equals 100 units or 1.0 mL, while 20 mg equals 200 units or 2.0 mL. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
At the 10 mg/mL concentration shown here, 10 mg equals 100 units or 1.0 mL, while 20 mg equals 200 units or 2.0 mL. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
Important distinction:
The research-use dosing framework shown here is separate from FDA-approved Forzinity dosing. Elamipretide has an approved clinical regimen for Barth syndrome, but that does not validate other SS-31 dosing schedules or indications.
The research-use dosing framework shown here is separate from FDA-approved Forzinity dosing. Elamipretide has an approved clinical regimen for Barth syndrome, but that does not validate other SS-31 dosing schedules or indications.
Why use this version?
Practical Approach
This is the practical real-world approach. It keeps the math simple and reflects the dose range most commonly discussed for balancing cost and effectiveness.
What to Expect
Effects may begin within 1–2 weeks, but consistency matters more than exact clock timing with SS-31.
Higher Research-Use Range
10 mg Vial + 1.0 mL BAC Water → 10 mg/mL → 1 Unit = 0.1 mg
Research-Use Setup
Vial
10 mg
Water
1.0 mL bacteriostatic water
Concentration
10 mg/mL
Conversion
1 unit = 0.1 mg / 100 mcg
Higher Research-Use Reference
5 mg
50 units / 0.50 mL
10 mg
100 units / 1.00 mL
15 mg
150 units / 1.50 mL total
20 mg
200 units / 2.00 mL total
Important Evidence Distinction:
These amounts are shown as research-use conversion references, not as a clinically validated dose-escalation schedule. Human elamipretide studies have used indication-specific doses and treatment durations, and published research does not establish a standard progression from 5 mg to 10 mg to 15 mg to 20 mg over 8–12 weeks.
These amounts are shown as research-use conversion references, not as a clinically validated dose-escalation schedule. Human elamipretide studies have used indication-specific doses and treatment durations, and published research does not establish a standard progression from 5 mg to 10 mg to 15 mg to 20 mg over 8–12 weeks.
Human Clinical Context
Elamipretide has substantial human clinical research using once-daily
subcutaneous administration. Clinical dose and duration have varied
according to the disease and study design rather than following a
universal dose-escalation schedule.
In primary mitochondrial myopathy research, 40 mg once daily
subcutaneously was studied for 4 weeks in MMPOWER-2, including a
4-week washout period between treatment phases.
The Phase 3 MMPOWER-3 trial studied 40 mg once daily subcutaneously
for 24 weeks. The trial did not meet its primary exercise or fatigue
endpoints, although treatment was generally well tolerated.
Other human studies, including age-related macular degeneration
research, have also evaluated 40 mg subcutaneously once daily for
approximately 24 weeks.
FDA-approved Forzinity (elamipretide) uses 40 mg subcutaneously once
daily for adult and pediatric patients with Barth syndrome weighing
at least 30 kg. The approved product is supplied at 80 mg/mL,
making the 40 mg dose a 0.5 mL injection.
Important distinction:
The 40 mg clinical dose is disease-specific and should not be interpreted as validation of the 5–20 mg research-use ranges shown above. Likewise, the lower research-use ranges should not be presented as scaled-down versions of the FDA-approved Barth syndrome regimen.
The 40 mg clinical dose is disease-specific and should not be interpreted as validation of the 5–20 mg research-use ranges shown above. Likewise, the lower research-use ranges should not be presented as scaled-down versions of the FDA-approved Barth syndrome regimen.
Volume Note:
At 10 mg/mL, 10 mg equals 1.0 mL, 15 mg equals 1.5 mL, and 20 mg equals 2.0 mL total. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
At 10 mg/mL, 10 mg equals 1.0 mL, 15 mg equals 1.5 mL, and 20 mg equals 2.0 mL total. Volumes above 1.0 mL exceed the capacity of a standard 1 mL U-100 insulin syringe.
FDA-Approved Elamipretide Use
FDA-Approved Elamipretide Use
Brand
Forzinity
Approved Indication
Barth syndrome
Eligible Weight
30 kg or greater
Approved Dose
40 mg once daily
Route
Subcutaneous
Clinical context:
Forzinity received FDA accelerated approval for improving muscle strength in certain patients with Barth syndrome. This approved regimen is disease-specific and should not be treated as a general SS-31 longevity, recovery, or mitochondrial-optimization protocol.
Forzinity received FDA accelerated approval for improving muscle strength in certain patients with Barth syndrome. This approved regimen is disease-specific and should not be treated as a general SS-31 longevity, recovery, or mitochondrial-optimization protocol.
How to Use SS-31 (Cycle, Timing & Injection)
Research Duration & Reassessment
Research-Use Framework
4–12 weeks
Human Clinical Studies
Have ranged from days to many months
Required Off-Period
No universal clinical break established
Approved Barth Use
Daily ongoing treatment per prescribing information
Best Time to Take
Once-daily administration is common in human elamipretide research
A specific morning vs evening advantage has not been established
Clinical and research protocols generally emphasize consistent administration rather than a specific clock time
Split AM / PM dosing is not an established standard human elamipretide regimen
Where to Inject
Subcutaneous administration is used in human elamipretide studies and approved Forzinity use
Common subcutaneous areas include the abdomen and thigh
Rotate injection sites to reduce repeated irritation in the same area
Larger research-use volumes may exceed the capacity of a standard 1 mL syringe and require additional volume planning
When to Use
Elamipretide has been studied in mitochondrial and metabolic disease research
Human studies have investigated fatigue, exercise performance, muscle function, and mitochondrial bioenergetics
Clinical outcomes have varied significantly depending on the condition being studied
FDA-approved use is specifically for eligible patients with Barth syndrome; other uses should not be assumed to have the same level of clinical evidence
Simple Approach:
The research-use framework shown on this page begins with a lower daily amount before moving into a broader research range. Human elamipretide studies have used very different doses and treatment durations depending on the disease being studied, so there is no single universal SS-31 dose-escalation or cycling protocol.
The research-use framework shown on this page begins with a lower daily amount before moving into a broader research range. Human elamipretide studies have used very different doses and treatment durations depending on the disease being studied, so there is no single universal SS-31 dose-escalation or cycling protocol.
Real-World vs Clinical Dosing
Research-Use Ranges → Human Clinical Research → FDA-Approved Barth Syndrome Use
Research-Use vs Clinical Context
5–20 mg
Commonly discussed research-use range; not an FDA-approved general mitochondrial protocol
Clinical Research
Human elamipretide studies have evaluated different doses depending on the disease and study design
40 mg Daily
Used in multiple human clinical studies
FDA-Approved Dose
40 mg subcutaneous once daily for eligible patients with Barth syndrome
Important distinction:
A higher elamipretide dose should not automatically be interpreted as producing a stronger mitochondrial effect. Dose, response, and clinical outcomes depend on the condition being studied, and results have varied across human trials.
A higher elamipretide dose should not automatically be interpreted as producing a stronger mitochondrial effect. Dose, response, and clinical outcomes depend on the condition being studied, and results have varied across human trials.
Simple takeaway:
The 5–20 mg amounts discussed in research-use settings should be kept separate from clinically studied and FDA-approved elamipretide dosing. The 40 mg approved regimen is specific to eligible patients with Barth syndrome and does not establish 40 mg as an optimal dose for longevity, energy, recovery, or general mitochondrial support.
The 5–20 mg amounts discussed in research-use settings should be kept separate from clinically studied and FDA-approved elamipretide dosing. The 40 mg approved regimen is specific to eligible patients with Barth syndrome and does not establish 40 mg as an optimal dose for longevity, energy, recovery, or general mitochondrial support.
Why SS-31 Doses Look Different From Many Peptides
Why the Amounts Can Look Higher
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide with a mechanism that differs from many receptor-signaling peptides.
Elamipretide selectively associates with cardiolipin in the inner mitochondrial membrane, where its effects on mitochondrial structure and bioenergetics have been studied.
Human clinical studies have evaluated elamipretide at milligram-level doses, including daily subcutaneous administration.
The milligram amounts used with elamipretide should not be directly compared with the microgram amounts used for peptides that act through different targets and pharmacologic mechanisms.
A higher numerical dose does not necessarily mean a peptide is stronger, weaker, less efficient, or expected to produce a greater clinical effect.
Simple takeaway:
Peptide doses cannot be meaningfully compared by milligrams alone. SS-31 has its own pharmacology, clinical research history, and dose-response profile, so its dosing should be evaluated independently rather than compared directly with microgram-dosed peptides.
Peptide doses cannot be meaningfully compared by milligrams alone. SS-31 has its own pharmacology, clinical research history, and dose-response profile, so its dosing should be evaluated independently rather than compared directly with microgram-dosed peptides.
Reconstitution & Dose Conversion (10 mg Vial)
Reconstitution Setup
Vial
10 mg
Water
1.0 mL bacteriostatic water
Concentration
10 mg/mL
Conversion
1 unit = 0.1 mg / 100 mcg
Conversion Reference
5 mg
50 units / 0.50 mL
7.5 mg
75 units / 0.75 mL
10 mg
100 units / 1.00 mL
15 mg
150 units / 1.50 mL total
20 mg
200 units / 2.00 mL total
Volume Note:
A standard 1 mL U-100 insulin syringe holds a maximum of 100 units or 1.0 mL. At this concentration, amounts above 10 mg exceed that single-syringe volume. The values above are mathematical conversion references and do not establish an appropriate dose.
A standard 1 mL U-100 insulin syringe holds a maximum of 100 units or 1.0 mL. At this concentration, amounts above 10 mg exceed that single-syringe volume. The values above are mathematical conversion references and do not establish an appropriate dose.
Reconstitution Steps
Draw 1.0 mL bacteriostatic water using a sterile syringe
Add the water slowly down the inside wall of the vial
Gently swirl or roll the vial rather than shaking
Allow the contents to dissolve completely before use
Refrigerate after reconstitution at 2–8°C
Important distinction:
This reconstitution example applies to the research-use 10 mg vial shown on this page. It is not the formulation or preparation method for FDA-approved Forzinity.
This reconstitution example applies to the research-use 10 mg vial shown on this page. It is not the formulation or preparation method for FDA-approved Forzinity.
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (unmixed)
Store at −20°C (−4°F) for long-term stability
Short-term storage: 2–8°C (36–46°F) acceptable
Keep dry, sealed, and protected from light
Avoid repeated temperature changes
Reconstituted (mixed)
Store at 2–8°C (36–46°F)
Use within ~30 days for best stability
Do not freeze after mixing
Avoid shaking or agitation
Discard if cloudy, discolored, or particulate matter appears
Best Practice
Handling
Protect from light and keep handling consistent to reduce degradation risk. Limit exposure to air and contamination.
Temperature
Avoid unnecessary room-temperature exposure once mixed. Keep refrigerated between uses and return immediately after drawing doses.
Stability Insight
SS-31 is relatively stable compared to many peptides, but maintaining consistent cold storage helps preserve potency and consistency over time.
Time Between Cycles
Research Duration & Reassessment
Research-Use Framework
4–12 weeks
Commonly Discussed Break
2–4 weeks when cycling
Required Off-Period
No universal clinical break established
Clinical Context
Human studies have also used continuous daily treatment for longer periods
Why reassess?
The 4–12 week cycle and 2–4 week break shown here represent a research-use framework rather than a clinically required SS-31 schedule. Human elamipretide studies have used different treatment durations depending on the condition being studied, and FDA-approved Barth syndrome treatment uses ongoing once-daily administration.
The 4–12 week cycle and 2–4 week break shown here represent a research-use framework rather than a clinically required SS-31 schedule. Human elamipretide studies have used different treatment durations depending on the condition being studied, and FDA-approved Barth syndrome treatment uses ongoing once-daily administration.
Reasons to Reassess
No meaningful change is being observed for the defined research goal
Injection-site reactions or other adverse effects become persistent
The original research or support period has ended
Continued use no longer has a clearly defined purpose
Monitoring During Use
Response & Tolerability
Energy levels and fatigue
Exercise tolerance and physical function
Recovery and changes relevant to the research goal
Injection-site redness, pain, swelling, itching, or irritation
Any new or unexpected systemic symptoms
Signs of hypersensitivity or allergic reaction
Clinical context:
Injection-site reactions are among the most commonly reported adverse effects with clinical elamipretide use. FDA labeling also includes hypersensitivity reactions, so monitoring should include tolerability rather than focusing only on perceived energy or performance changes.
Injection-site reactions are among the most commonly reported adverse effects with clinical elamipretide use. FDA labeling also includes hypersensitivity reactions, so monitoring should include tolerability rather than focusing only on perceived energy or performance changes.
Benefits
Elamipretide has been extensively studied for mitochondrial bioenergetics and cardiolipin-related signaling
Human clinical trials have evaluated elamipretide across primary mitochondrial disease, Barth syndrome, age-related macular degeneration, and other mitochondrial disorders
Elamipretide is FDA-approved to improve muscle strength in certain patients with Barth syndrome
Clinical efficacy has varied by indication, and several trials did not meet their primary endpoints
Evidence from Barth syndrome should not automatically be generalized to longevity, energy, recovery, or healthy-aging use
Potential Side Effects
Injection-site reactions are among the most commonly reported adverse effects
Redness, pain, swelling, itching, bruising, or hives may occur at the injection site
Hypersensitivity reactions, including serious allergic reactions, have been reported
Safety depends on dose, indication, formulation, kidney function, and clinical context
Research-use preparations should not be assumed to have the same safety, purity, or formulation as FDA-approved Forzinity
Stacking Strategies
Longevity: SS-31 + MOTS-c
Recovery: SS-31 + BPC-157
Metabolic: SS-31 + NAD+
Important Notes
SS-31 and elamipretide refer to the same mitochondria-targeting tetrapeptide; elamipretide is also marketed as Forzinity.
Forzinity received FDA accelerated approval in 2025 for improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
The FDA-approved dose is 40 mg subcutaneously once daily for eligible patients, with dose modification in certain adults with severe renal impairment.
The approved Barth syndrome regimen should not be generalized to longevity, recovery, healthy-aging, or mitochondrial-optimization use.
Human trials have used a wide range of doses and treatment durations depending on the disease and study design.
Research-use vial concentrations and reconstitution methods are not equivalent to the commercial Forzinity formulation.
Important Disclaimer
SS-31 (Elamipretide) is an investigational peptide and not FDA-approved. This content is for educational purposes only.
Research & References
Primary Research
- Szeto HH, Schiller PW. Novel Therapies Targeting Inner Mitochondrial Membrane—From Discovery to Clinical Development. Pharmaceutical Research. 2011.
- Szeto HH. First-in-Class Cardiolipin-Protective Compound as a Therapeutic Agent to Restore Mitochondrial Bioenergetics. British Journal of Pharmacology. 2014.
- Zhao K, Zhao GM, Wu D, et al. Cell-Permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane Inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury. Journal of Biological Chemistry. 2004.
- Karaa A, Haas R, Goldstein A, et al. Randomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy. Neurology. 2018.
- Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. 2017.
Research Note: SS-31 (Elamipretide) has undergone extensive clinical trial testing across mitochondrial myopathy, heart failure, kidney disease, and age-related eye disease, but it remains investigational and has not received FDA approval for any indication. Results from late-stage efficacy trials have been mixed.
Comments
Post a Comment